Truist Securities sees Roivant Sciences (ROIV) shares up today on positive brepocitinib data
Tweet Send to a Friend
Truist Securities analyst Robyn Karnauskas reiterated a Buy rating and $23.00 price target on Roivant Sciences (NASDAQ: ROIV), saying positive ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
